302 related articles for article (PubMed ID: 33927717)
1. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
Front Immunol; 2021; 12():644637. PubMed ID: 33927717
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
3. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
4. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
5. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
6. The neoepitope landscape of breast cancer: implications for immunotherapy.
Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
[TBL] [Abstract][Full Text] [Related]
7. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
8. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
9. TANTIGEN: a comprehensive database of tumor T cell antigens.
Olsen LR; Tongchusak S; Lin H; Reinherz EL; Brusic V; Zhang GL
Cancer Immunol Immunother; 2017 Jun; 66(6):731-735. PubMed ID: 28280852
[TBL] [Abstract][Full Text] [Related]
10. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
11. ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
Rao AA; Madejska AA; Pfeil J; Paten B; Salama SR; Haussler D
Front Immunol; 2020; 11():483296. PubMed ID: 33244314
[TBL] [Abstract][Full Text] [Related]
12. TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes.
Zhang G; Chitkushev L; Olsen LR; Keskin DB; Brusic V
BMC Bioinformatics; 2021 Apr; 22(Suppl 8):40. PubMed ID: 33849445
[TBL] [Abstract][Full Text] [Related]
13. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of neoepitopes.
Teku GN; Vihinen M
Sci Rep; 2018 Aug; 8(1):12735. PubMed ID: 30143704
[TBL] [Abstract][Full Text] [Related]
16. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
17. Neoepitopes-based vaccines: challenges and perspectives.
Alcazer V; Bonaventura P; Tonon L; Wittmann S; Caux C; Depil S
Eur J Cancer; 2019 Feb; 108():55-60. PubMed ID: 30648630
[TBL] [Abstract][Full Text] [Related]
18. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
19. Developing neoantigen-targeted T cell-based treatments for solid tumors.
Yamamoto TN; Kishton RJ; Restifo NP
Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
[TBL] [Abstract][Full Text] [Related]
20. TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.
Wu J; Chen W; Zhou Y; Chi Y; Hua X; Wu J; Gu X; Chen S; Zhou Z
Genomics Proteomics Bioinformatics; 2023 Apr; 21(2):259-266. PubMed ID: 36209954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
